Michael Barbella, Managing Editor02.06.24
Envoy Medical Inc. has been awarded a patent, “Implantable Cochlear System with Inner Ear Sensor,” (Document ID: US 11806531 B2) another in a growing number of patents the company has either applied for or secured as part of its implantable hearing devices technology portfolio.
“We are excited to announce this new patent, which gives us an additional opportunity to evolve and grow our designs over time. We’ve made no secret of our intent to disrupt the hearing implant market with our fully implanted Acclaim cochlear implant, but we also have a strategy to maintain that momentum with additional advances in the implantable hearing device market for years to come,” Envoy Medical CEO Brent Lucas said.
Envoy Medical’s fully implanted technology includes a sensor designed to leverage the natural anatomy of the ear instead of a microphone to capture sound. The Acclaim is designed to address severe to profound sensorineural hearing loss that is not adequately addressed by hearing aids. The Acclaim is expected to be indicated for adults who have been deemed adequate candidates by a qualified physician.
Current cochlear implants rely on bulky external hardware that are held in place on the head by a magnet, which can cause discomfort and may not be suitable for all activities, including sleeping, showering, swimming, strenuous activity and other common daily events. Envoy Medical’s device seeks to alleviate these limitations by being the first fully implanted cochlear implant (sometimes referred to as a totally implanted cochlear implant or “TICI”). By using an implanted middle ear sensor and an implanted rechargeable power supply, Acclaim aims to eliminate the need for any externally worn components.
Acclaim was granted Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) and is currently in an early feasibility study at Mayo Clinic (Rochester, Minn.).
The fully implanted Acclaim Cochlear Implant is an investigational device limited by U.S. law to investigational use.
Envoy Medical Inc., headquartered in White Bear Lake, Minn., is a hearing health company providing innovative medical technologies.
“We are excited to announce this new patent, which gives us an additional opportunity to evolve and grow our designs over time. We’ve made no secret of our intent to disrupt the hearing implant market with our fully implanted Acclaim cochlear implant, but we also have a strategy to maintain that momentum with additional advances in the implantable hearing device market for years to come,” Envoy Medical CEO Brent Lucas said.
Envoy Medical’s fully implanted technology includes a sensor designed to leverage the natural anatomy of the ear instead of a microphone to capture sound. The Acclaim is designed to address severe to profound sensorineural hearing loss that is not adequately addressed by hearing aids. The Acclaim is expected to be indicated for adults who have been deemed adequate candidates by a qualified physician.
Current cochlear implants rely on bulky external hardware that are held in place on the head by a magnet, which can cause discomfort and may not be suitable for all activities, including sleeping, showering, swimming, strenuous activity and other common daily events. Envoy Medical’s device seeks to alleviate these limitations by being the first fully implanted cochlear implant (sometimes referred to as a totally implanted cochlear implant or “TICI”). By using an implanted middle ear sensor and an implanted rechargeable power supply, Acclaim aims to eliminate the need for any externally worn components.
Acclaim was granted Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) and is currently in an early feasibility study at Mayo Clinic (Rochester, Minn.).
The fully implanted Acclaim Cochlear Implant is an investigational device limited by U.S. law to investigational use.
Envoy Medical Inc., headquartered in White Bear Lake, Minn., is a hearing health company providing innovative medical technologies.